Fujifilm
VC Fund
Tokyo, Japan
Fujifilm is a VC fund in Tokyo focused on Biotechnology and Health Care. Fujifilm develops and sells consumer products and business products related to photography. Fujifilm Holdings Corporation is a Japanese multinational photography and imaging company. The company serves various industries, including medical, graphic arts, optics, enterprise storage, motion picture, and photography.The company’s consumer productsare categorized as digital cameras and accessories, film photography, Instax photography, and binoculars. Its business products are categorized as medical systems, Fujinon endoscopy, microfilm, data storage, graphic arts and printing, professional video, optical devices, specialty chemicals, printing imaging colorants, and more. Color films, digital cameras, photofinishing equipment, color papers, photofinishing chemicals, medical imaging equipment, graphic arts equipment and materials, flat panel displays, and photocopiers and printers are some products developed by Fujifilm USA.Fujifilm USA is based in Minato-ku, Tokyo, Japan.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 28%
Last updated:
For AI agents: llms.txt
Industries Fujifilm invests in
Stages Fujifilm invests in
Countries Fujifilm invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Series A
- $3.3M–$250M
- Corporate Round
- $1.3M–$1.7B
- Venture - Series Unknown
- $2.9M–$36M
Investment Focus
Industry
- Biotechnology 13 (52%)
- Health Care 11 (44%)
- Medical 9 (36%)
- Medical Device 7 (28%)
- Manufacturing 5 (20%)
Stage
- Series A 7 (28%)
- Venture - Series Unknown 6 (24%)
- Corporate Round 4 (16%)
- Series B 3 (12%)
- Funding Round 2 (8%)
Country
- Japan 12 (48%)
- United States 6 (24%)
- China 1 (4%)
- Israel 1 (4%)
- Austria 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Keiji Mihayashi
Corporate Vice President
|
Corporate Vice President | Total investments: 0 | Find email | |
Kenji Sukeno
Corporate Vice President; President & Chief Operating Officer
|
Corporate Vice President; President & Chief Operating Officer | Total investments: 0 | Find email | |
Kris Williams
Senior Talent Acquisition Recruiter
|
Senior Talent Acquisition Recruiter | Total investments: 0 | Find email | |
|
Morihiro Atsumi
Corporate Vice President
|
Corporate Vice President | Total investments: 0 | Find email | |
|
Norio Shibata
Corporate Vice President
|
Corporate Vice President | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | $3.5M / Venture - Series Unknown / Mar 12, 2026 | ||
| Rapidus is an Electronic component research, development, design, production, and sales that includes semiconductor elements and integrated circuits. Environmentally friendly, energy-saving semiconductors and semiconductor manufacturing technology are being researched and developed. Human resource development and training for the semiconductorsector. | $1.7B / Corporate Round / Feb 27, 2026 | ||
| Ripcord turns documents into powerful data. As a disruptor in the document intelligence market, Ripcord’s AI-driven platform harnesses proprietary robotics, generative AI, and cloud software to digitize and accurately derive vital information from paper and digital documents. Founded out of NASA research, Ripcord is backed by leading investorsincluding Kleiner Perkins, Google Ventures, Icon Ventures, Lux Capital, MUIP, and Apple co-founder Steve Wozniak. | $32M / Series C / Apr 16, 2024 | ||
| Tome Biosciences is a biotechnology company that develops programmable gene insertion technology. Using CRISPR, its technologies allow them to insert any genetic sequence of any size at any location into any genome. | $213M / Series A / Dec 12, 2023 | ||
| 24M Technologies develops energy storage systems for grid and transportation applications. It offers binder-free semisolid electrodes and unit cells, eliminating the need for hydro or pyrometallurgical processes for battery recycling. It also helps direct in-plant reuse of active material for end-of-life recycling. | $56.8M / Series E / May 27, 2021 | ||
| CUORiPS is a company developing new medical care based on world's cutting-edge technology originated in Japan. | $14.7M / Venture - Series Unknown / Mar 16, 2021 | ||
| Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics. | $3.3M / Series A / Jun 04, 2020 | ||
| Nanox offers the Nanox System as a preventative healthcare Medical Screening As A Service (MSaaS). Nanox field-effect cathode technology was originally developed for use in high-definition flat panel displays. Over time, the manufacturing processes were ported from glass to silicon, enabling enormous increases in power density and uniformity.After more than 20 years of research and development, with over $1B invested, their team of engineers has developed unique intellectual property, patents, and capability to design and build high-powered field-effect cathodes that outperform all previous efforts. Nanox’s proprietary cold cathode technology greatly expands the capabilities of X-ray imaging. At the core of their high-powered cold cathode is a “chip” of nano-scale structures created using proprietary nanofabrication techniques. The chip is designed to support various use cases of medical imaging and will be supported by peripheral technologies in order to translate their benefits into various real-world applications. | $26M / Series B / Jan 16, 2020 | ||
| Lunit, abbreviated from “learning unit,” is a venture company devoted to developing advanced software for medical data analysis and interpretation via cutting-edge deep learning technology. The company's main area of expertise lies in processing medical imaging data. It envisions a near future when its systems will greatly help physicians makeaccurate, consistent, and efficient clinical decisions, not limited to diagnoses, through our data-driven imaging biomarker technology. The high level of our deep learning technology has been well demonstrated, ranked top 5 at ImageNet Challenge 2015, which is the world’s largest and most prestigious image recognition competition. What distinguishes our technology from that of other similar parties is the full accommodation of weakly labeled data, challenging the boundaries of human understanding in terms of pattern recognition. | $4.2M / Series B / Nov 30, 2019 | ||
| Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer. The company's genetically-engineered, iPSC-derived immune effector cell products are designed to specifically target hematologic and solid cancers by harnessing the power of adult stem cells, providing patients with an unparalleled opportunityto advance the course of cancer care. | $250M / Series A / Jul 01, 2019 | ||
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Fujifilm invest in?
Fujifilm invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Venture - Series Unknown stage. Most of the 25 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Fujifilm invest in?
Fujifilm typically joins rounds of $3.3M–$250M at Series A, $1.3M–$1.7B at Corporate Round and $2.9M–$36M at Venture - Series Unknown. These are whole funding-round sizes, not Fujifilm's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Fujifilm took part in.
How do I contact Fujifilm?
Public channels for Fujifilm include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fujifilm?
The team at Fujifilm includes Keiji Mihayashi (Corporate Vice President), Kenji Sukeno (Corporate Vice President; President & Chief Operating Officer) and Kris Williams (Senior Talent Acquisition Recruiter), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
